Compare AU
Compare FSML vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are FSML and CURE. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
FSML | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 7 | 78 |
Median incremental investment | $855.00 | $640.11 |
Median investment frequency | Weekly | Monthly |
Median total investment | $2,300.09 | $1,274.70 |
Average age group | > 35 | > 35 |
Key Summary
FSML | CURE | |
|---|---|---|
Strategy | The fund's investment portfolio concentrates primarily on small cap equity. The Fund aims to outperform the S&P/ ASX Small Ordinaries Accumulation Index over the medium to long term | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 27.78m in AUM and 125 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Firetrail Aust Small Companies Fund - Active ETF (100 %) | Natera Inc (2.73 %) Alnylam Pharmaceuticals Inc (2.65 %) Vertex Pharmaceuticals Inc (2.64 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0 % | 0.45 % |
Key Summary
FSML | CURE | |
|---|---|---|
Issuer | Firetraill | Global X |
Tracking index | S&P/ASX Small Ordinaries Accumulation Index - AUD - Benchmark TR Gross | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0 % | 0.45 % |
Price | $1.69 | $42.49 |
Size | N/A | $28.994 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | - % | 4.24 % |
Market | ASX | ASX |
First listed date | 17/11/2024 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
FSML | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 7 | 78 |
Median incremental investment | $855.00 | $640.11 |
Median investment frequency | Weekly | Monthly |
Median total investment | $2,300.09 | $1,274.70 |
Average age group | > 35 | > 35 |
Pros and Cons
FSML | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
FSML | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |